



## JIM symposium: Innovative Payment Models in Alzheimer's Disease

### Are innovative payment models required to give patients access to potential disease-modifying therapies for Alzheimer's disease?

Several potentially disease-modifying therapies (DMT) for Alzheimer's disease (AD) are currently in final stages of clinical development. If successful, difficult questions will need to be answered regarding how DMT will be used and reimbursed. Such challenges are not unique to the field of AD; however, the scale of the issue would be unparalleled due to the high prevalence, enormous unmet medical need and challenges in determining the value of treatment and aligning the incentives of the multiple stakeholders involved. This symposium will provide a critical assessment of the applicability of innovative payment models to AD DMT, and develop proposals for which models can be considered under different circumstances.

**Date :** November 11, 2022, 09:00-17:00.

**Location :** Nobel Forum, Karolinska Institutet, Stockholm, Sweden

**Admission :** Free, **pre-registration required to [gunilla.johansson@ki.se](mailto:gunilla.johansson@ki.se)** (number of participants limited)

Time	Title	Speakers
09.00-09.15	Welcome	Bengt Winblad, Karolinska Institutet
09.15-09.30	Introduction to workshop and objectives	Linus Jönsson, Karolinska Institutet
09.30-09.45	The socioeconomic impact of Alzheimer's Disease	Anders Wimo, Karolinska Institutet
09.45-10.15	Determining the value of disease-modifying therapies for Alzheimer's Disease	Will Herring, RTI and Karolinska Institutet (TBC)
10.15-10.45	What are the challenges with reimbursement of disease-modifying therapies for Alzheimer's Disease?	Niklas Hedberg, Dental and Pharmaceutical Benefits Agency, chair of EUnetHTA.
10.45-11.15	Coffee break	
11.15-11.45	Experience with outcomes-based payment models in chronic progressive disease	Amanda Cole, Office of Health Economics
11.45-12.00	Questions, discussion	
12.00-13.00	Lunch	
13.00-13.30	Innovative payment models: beyond payment for outcomes	Joakim Ramsberg, Swedish Brain Foundation
13.30-14.00	Innovative payment models – the US experience	Mark McClellan, Duke University
14.00-15.00	Industry panel: innovative payment models, promises and experiences	Chair: Linus Jönsson Panel members to be announced later
15.00-15.30	Coffee break	
15.30-16.00	Real-world data for outcomes-based reimbursement schemes in AD	Pieter-Jelle Visser, UMC Amsterdam
16.00-16:45	Roundtable discussion: future payment models for AD therapies	All speakers
16:45-17:00	Wrap-up and conclusions	Bengt Winblad, Linus Jönsson